 |
|---|
MBF
THERAPEUTICS
™
Next Generation Immunotherapeutics™
MBF Therapeutics is an immunotherapeutic company focused on animal and human health applications of its innovative
T-Max™ immunotherapeutic DNA vaccine platform to create disruptive products for infectious disease and cancer. Initial development is focused on highly efficacious, universal vaccines that prevent significant current and new infectious diseases in livestock and humans.
ABOUT US & OUR ADVANTAGE
BUSINESS DESCRIPTION
MBFT is developing proprietary immunomodulating and checkpoint inhibitor immunotherapy technology for cancer and infectious diseases in animals. Based upon our animal health experiences we will develop human health vaccines through product specific subsidiaries.
Using our T-Max™ platform we create DNA vaccines that elicit T-cell responses that precisely target selected antigens to elicit durable cell-mediated immunity.
Our proprietary, nonviral CaptaVax ™ delivery system is a powerful platform technology with which multiple innovative products are being developed.
MBFT’s business strategy is built upon collaborations. During 2020 we signed collaboration agreements with Smithfield Foods (swine vaccines), African Swine Fever (ASF experts), and a Next-Generation SARS CoV-2 vaccine (a cross functional team).
SCIENCE & TECHNOLOGY
OVERVIEW
MBFT has T-Max™ created a suite of proprietary Checkpoint Inhibitors (CPI) and Innate Immune Cell targeting Immunomodulators coupled with CaptaVax™, a proprietary, highly effective carrier/adjuvant system to create a new generation of protective and therapeutic T-cell based DNA vaccines. The company has exclusive rights in animal health to CPI technology from the Wistar Institute and Southwest Research Institute and is expanding its core technology portfolio with the addition of other checkpoint inhibitors, immunomodulators and proprietary delivery systems that further strengthen its IP position. Collectively, these technologies coupled with specifically selected highly conserved protective antigens and technical know-how provide MBFT with the opportunity to sustain its leadership in this field and develop breakthrough products for the emerging infectious disease and companion animal cancer markets. A comprehensive listing of MBFT’s intellectual property is available upon request. This includes in-licensed and in-house derived IP.
IN THE PIPELINE
TEAM
PRODUCT
DESCRIPTION
TIMING
MBFT-305
Porcine Respiratory and Reproductive Syndrome vaccines
Research phase
CVXD-001
CaptaVax autogenous vaccines for swine diseases
Clinical trial ongoing, potential sales 2022
MBFT-304
African Swine Fever vaccine
Research phase | Portential approval 2023
COVE-001
Next Generation SARS CoV-2 vaccine for humans
Preclinical studies ongoing | Goal is IND approval 2022
MBFT-202
Canine Multi-tumor sarcoma vaccine
Research phase
LEADERSHIP TEAM
President & Co-Founder
CEO RheoGene; at Rohm and Haas – Bus. Director Biotech, Global Business Manager, Global Business Mgr. Pyridines
THOMAS
TILLETT
PhD - CSO | Co-Founder
Co-founder RheoGene, Immunotope, Rohm & Haas
LORRAINE
KELLER
BOARD OF DIRECTORS
CEO | MBFT
THOMAS
TILLETT
CEO | Biovista
Dr. ARIS
PERSIDIS
former CEO
Marinus Pharmaceuticals
CHRIS
CASHMAN
CEO | Med Aditus
Dr. DHIREN
THAKKER
Watermill Asset Management
CHRIS
BUNGE
Ben Franklin Tech Partners (Board Observer)
TONY
GREEN
COLLABORATIONS & PARTNERSHIPS
MBFT’s business strategy is based upon utilizing collaborations and partnerships to significantly expand our expertise and capabilities. Below is a listing of companies or projects we have announced collaborations or partnerships with, most of these announced in 2020.
OneWorld Biotech – MBFT has a master R&D agreement with this Warminster, Pap-based CRO that works in collaboration with MBFT’s CSO to design and create our products.
Diamond Animal Health – MBFT has a master development agreement with DAH to scale up and manufacture our animal health vaccines for sale and distribution in NAR.
https://www.heska.com/product/manufacturing-services
Smithfield Foods – The largest pork producer in the world is collaborating on th development and testing of innovative vaccines for serious swine infectious diseases in NAR. https://www.mbftherapeutics.com/jan-10-2020
African Swine Fever – MBFT assembled a team of African Swine Fever Virus (ASFV) experts and leading researchers to develop an effective, broad-spectrum ASFV vaccine, leveraging MBF Therapeutics’ proprietary immunotherapy platform and delivery system. The team includes Dr. Bob Rowland (University of Illiniois), Dr. Megan Neiderwerder (Kansas State Univ.), Dr. Luca Popescu (MRI Global), Dr. Tobias Kaeser (NCSU), and Dr. Malla Padidam (OneWorld Biotech)
https://www.mbftherapeutics.com/apr-1-2020
Next-Generation SARS CoV-2 - a collaboration of life science industry experts for the advancement of the next-generation SARS CoV-2 vaccine toward an investigational new drug (IND). The team includes: MRIGlobal – pre-clinical testing, Rymedi – provision of integrated data and diagnostics platform, SSI Strategy – optimized clinical development planning; project management of the IND process, Aldevron– DNA vaccine formulation; scale-up and manufacturing.
https://www.mbftherapeutics.com/july-23-2020
Southwest Research Institute – In-licensed SwRI’s novel calcium phosphate nanoparticle delivery system and collaborating on novel methods to scale up commercial manufacturing and on grant funding opportunities.
